The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Pan Zhen-hu - One of the best experts on this subject based on the ideXlab platform.
-
valuation of Clinical Application of Detective System of Multi-Tumor Markers Protein Chip for ovarian cancer
Modern Preventive Medicine, 2012Co-Authors: Pan Zhen-huAbstract:OBJECTIVE To evaluate the clinical applications to early diagnosis and monitoring prognosis with multi-Tumor Markers protein chip in ovarian cancer.METHODS The serum levels of Tumor Markers were measured with the detective system in 100 patients with ovarian cancer 100 healthy women as control.Random negative samples detected by multi-Tumor Markers protein chip were also measured by E601.RESULTS The sensitivity of Tumor Markers was 83% in patients with ovarian cancer.There were two positive samples among 100 healthy women(the specificity was 98%).The level of Tumor Markers decreased significantly in the first 3-4 weeks in 83 cases of C-12-positive patients with ovarian cancer after radical surgery.But there were no significant difference among 3 months,6 months,and 12 months.CONCLUSION Multiple Tumor marker protein chip detection system could significantly improve the sensitivity and specificity for the diagnosis of ovarian cancer,and monitor the prognosis and therapeutic response,which is of important clinical significance.
Feng Luo - One of the best experts on this subject based on the ideXlab platform.
-
serum Tumor Markers for detection of hepatocellular carcinoma
World Journal of Gastroenterology, 2006Co-Authors: Lin Zhou, Jia Liu, Feng LuoAbstract:Hepatocellular carcinoma (HCC) is one of the most frequent malignant Tumors and is the second most common cause of cancer death in China. Therefore, it is very important to detect this disease and the recurrence at its earlier period. Serum Tumor Markers, as the effective method for detecting hepatocellular carcinoma for a long time, could be divided into 4 categories: oncofetal antigens and glycoprotein antigens; enzymes and isoenzymes; genes; and cytokines. Serum alpha fetoprotein (AFP) is the most widely used Tumor marker in detecting patients with hepatocellular carcinoma, and has been proven to have capability of prefiguring the prognosis. However, it has been indicated that AFP-L3 and DCP excel AFP in differentiating hepatocellular carcinoma from nonmalignant hepatopathy and detecting small hepatocellular carcinoma. Some Tumor Markers, such as human cervical cancer oncogene and human telomerase reverse transcriptase mRNA, have also been indicated to have higher accuracies than AFP. Furthermore, some other Tumor Markers, such as glypican-3, gamma-glutamyl transferase II, alpha-l-fucosidase, transforming growth factor-beta1, Tumor-specific growth factor, have been indicated to be available supplementaries to AFP in the detection. AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis. Some other Markers, such as gamma-glutamyl transferase mRNA, vascular endothelial growth factor, and interleukin-8, could also be used as available prognostic indicators, and the simultaneous determination of AFP and these Markers may detect the recurrence of HCC at its earlier period.
Lin Zhou - One of the best experts on this subject based on the ideXlab platform.
-
serum Tumor Markers for detection of hepatocellular carcinoma
World Journal of Gastroenterology, 2006Co-Authors: Lin Zhou, Jia Liu, Feng LuoAbstract:Hepatocellular carcinoma (HCC) is one of the most frequent malignant Tumors and is the second most common cause of cancer death in China. Therefore, it is very important to detect this disease and the recurrence at its earlier period. Serum Tumor Markers, as the effective method for detecting hepatocellular carcinoma for a long time, could be divided into 4 categories: oncofetal antigens and glycoprotein antigens; enzymes and isoenzymes; genes; and cytokines. Serum alpha fetoprotein (AFP) is the most widely used Tumor marker in detecting patients with hepatocellular carcinoma, and has been proven to have capability of prefiguring the prognosis. However, it has been indicated that AFP-L3 and DCP excel AFP in differentiating hepatocellular carcinoma from nonmalignant hepatopathy and detecting small hepatocellular carcinoma. Some Tumor Markers, such as human cervical cancer oncogene and human telomerase reverse transcriptase mRNA, have also been indicated to have higher accuracies than AFP. Furthermore, some other Tumor Markers, such as glypican-3, gamma-glutamyl transferase II, alpha-l-fucosidase, transforming growth factor-beta1, Tumor-specific growth factor, have been indicated to be available supplementaries to AFP in the detection. AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis. Some other Markers, such as gamma-glutamyl transferase mRNA, vascular endothelial growth factor, and interleukin-8, could also be used as available prognostic indicators, and the simultaneous determination of AFP and these Markers may detect the recurrence of HCC at its earlier period.
Susan E. Bates - One of the best experts on this subject based on the ideXlab platform.
-
Clinical applications of serum Tumor Markers.
Annals of internal medicine, 1991Co-Authors: Susan E. BatesAbstract:The pursuit of the ideal Tumor marker has generated many tests for use in the diagnosis and management of cancer, several of which are now widely available. Tumor Markers have five potential uses in patient care: They can be used for screening, for diagnosis, for establishing prognosis, for monitoring treatment, and for detecting relapse. The value of a marker in a given setting depends on two marker-related characteristics--sensitivity and specificity. The value of a marker in a particular malignancy also depends on the effectiveness of therapy for the malignancy. Tumor Markers have been used to screen for occult cancer but have proved to be valuable only in selected cancers. As diagnostic tools, Tumor Markers have limitations: Nearly all Markers can be elevated in benign disorders, and most Markers are not elevated in the early stages of malignancy. Extreme marker elevation often indicates a poor prognosis and in some malignancies can indicate the need for more aggressive treatment. Tumor Markers have their greatest value when used to monitor therapy in patients with widespread cancer. Nearly all Markers show some correlation with the clinical course of disease, with marker elevation in any stage declining to normal after a curative intervention. Recurrent disease can be accompanied by increased marker levels, but Markers can detect an occult recurrence in only a few diseases, thereby facilitating a second attempt at cure. Although it seems unlikely that an ideal Tumor marker will be identified for every malignancy, several workable Markers are already available. Increasing our knowledge about the capabilities and limitations of existing Markers will enable us to use them judiciously in the treatment of cancer.
Srdjan Novaković - One of the best experts on this subject based on the ideXlab platform.
-
Tumor Markers in clinical oncology
Radiology and Oncology, 2004Co-Authors: Srdjan NovakovićAbstract:The subtle differences between normal and Tumor cells are exploited in the detection and treatment of cancer. These differences are designated as Tumor Markers and can be either qualitative or quantitative in their nature. That means that both the structures that are produced by Tumor cells as well as the structures that are produced in excessive amounts by host tissues under the influence of Tumor cells can function as Tumor Markers. Speaking in general, the Tumor Markers are the specific molecules appearing in the blood or tissues and the occurrence of which is associated with cancer. According to their application, Tumor Markers can be roughly divided as Markers in clinical oncology and Markers in pathology. In this review, only Tumor Markers in clinical oncology are going to be discussed. Current Tumor Markers in clinical oncology include (i) oncofetal antigens, (ii) placental proteins, (iii) hormones, (iv) enzymes, (v) Tumor-associated antigens, (vi) special serum proteins, (vii) catecholamine metabolites, and (viii) miscellaneous Markers. As to the literature, an ideal Tumor marker should fulfil certain criteria - when using it as a test for detection of cancer disease: (1) positive results should occur in the early stages of the disease, (2) positive results should occur only in the patients with a specific type of malignancy, (3) positive results should occur in all patients with the same malignancy, (4) the measured values should correlate with the stage of the disease, (5) the measured values should correlate to the response to treatment, (6) the marker should be easy to measure. Most Tumor Markers available today meet several, but not all criteria. As a consequence of that, some criteria were chosen for the validation and proper selection of the most appropriate marker in a particular malignancy, and these are: (1) Markers' sensitivity, (2) specificity, and (3) predictive values. Sensitivity expresses the mean probability of determining an elevated Tumor marker level (over the "cut-off value") in a Tumor-bearing patient. Specificity expresses the mean probability that a normal Tumor marker value derives from a Tumor-free individual. The predictive value shows the applicability of a Tumor marker in a mixed group of patients. Many theoretical applications exist for Tumor Markers in clinical oncology. Clinically important utilization of Markers includes (i) early detection of the Tumor, (ii) differentiating benign from malignant conditions, (iii) evaluating the extent of the disease, (iv) monitoring the response of the Tumor to therapy, and (v) predicting or detecting the recurrence of the Tumor. Since no ideal Tumor Markers with adequate sensitivity and specificity currently exist, they are only exceptionally used in screening (prostate specific antigen - PSA). Nevertheless, Tumor Markers can play a crucial role in the detection of an early disease relapse and assessment of response to therapy in selected groups of patients. In monitoring the patients for disease recurrence, Tumor marker levels should be determined only when meaningful treatment is possible.
